Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells
- PMID: 15339974
- DOI: 10.1097/01.ASN.0000136778.32499.05
Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells
Abstract
The proximal tubular cells of the kidney are responsible for reabsorption of proteins from the tubular lumen. In a study using Opossum kidney (OK) cells, receptor-mediated protein endocytosis was reduced by statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, which are widely used for therapeutic reduction of plasma cholesterol levels. To explore the possible clinical relevance of the observations in OK cells, protein endocytosis in human kidney tubular cells was investigated in the presence and absence of statins. The uptake of FITC-labeled albumin in these cultures of human kidney tubular cells was investigated by microscopy, flow cytometry and spectrofluorometry. Protein uptake occurred selectively into proximal tubular cells while it was absent in distal tubular/collecting duct cells. Three statins (simvastatin, pravastatin, and rosuvastatin) significantly inhibited the uptake of protein in a concentration-dependent way. This inhibitory effect of statins could be prevented by the co-addition of mevalonate, the product of HMG-CoA reductase. This effect was not the result of a statin-induced cytotoxicity since cell-viability was unaffected. Finally, it was demonstrated that statins strongly inhibited cholesterol synthesis in the human kidney tubular cells. These data suggest that statins have the potential to inhibit albumin uptake by the human proximal nephron as a result of inhibition of HMG-CoA reductase in the proximal tubule cells. Taken into account the data of the accompanying manuscript this inhibitory effect most probably results from a reduced prenylation of some proteins critically involved in endocytosis. It is suggested that these data help to explain the occurrence of proteinuria in some patients treated with high statin doses.
Comment in
-
Statin induced proteinuria: renal injury or renoprotection?J Am Soc Nephrol. 2004 Sep;15(9):2502-3. doi: 10.1097/01.ASN.0000143720.71748.79. J Am Soc Nephrol. 2004. PMID: 15340001 No abstract available.
Similar articles
-
Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells.J Am Soc Nephrol. 2004 Sep;15(9):2258-65. doi: 10.1097/01.ASN.0000138236.82706.EE. J Am Soc Nephrol. 2004. PMID: 15339975
-
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.Am J Nephrol. 2007;27(1):15-23. doi: 10.1159/000098432. Epub 2007 Jan 5. Am J Nephrol. 2007. PMID: 17204833
-
Statin treatment and 3' polyadenylation of eNOS mRNA.Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2642-9. doi: 10.1161/ATVBAHA.107.154492. Epub 2007 Oct 4. Arterioscler Thromb Vasc Biol. 2007. PMID: 17916773
-
Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.Biomed Chromatogr. 2006 Mar;20(3):282-93. doi: 10.1002/bmc.561. Biomed Chromatogr. 2006. PMID: 16143964 Review.
-
Effects of statins on renal function.Am J Cardiol. 2006 Mar 1;97(5):748-55. doi: 10.1016/j.amjcard.2005.09.110. Epub 2006 Jan 11. Am J Cardiol. 2006. PMID: 16490450 Review.
Cited by
-
Statin therapy in renal disease: harmful or protective?Curr Atheroscler Rep. 2007 Jan;9(1):18-24. doi: 10.1007/BF02693936. Curr Atheroscler Rep. 2007. PMID: 17169242 Review.
-
Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.Eur Heart J. 2018 Jul 14;39(27):2526-2539. doi: 10.1093/eurheartj/ehy182. Eur Heart J. 2018. PMID: 29718253 Free PMC article. Review.
-
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseases.Drug Saf. 2014 Jul;37(7):481-500. doi: 10.1007/s40264-014-0169-4. Drug Saf. 2014. PMID: 24788803 Review.
-
Transient Proteinuria Induced by High-Dose Rosuvastatin.AACE Endocrinol Diabetes. 2025 May 19;12(2):125-127. doi: 10.1016/j.aed.2025.05.003. eCollection 2025 Jul-Aug. AACE Endocrinol Diabetes. 2025. PMID: 40786999 Free PMC article.
-
Endocytotic uptake of zoledronic acid by tubular cells may explain its renal effects in cancer patients receiving high doses of the compound.PLoS One. 2015 Mar 10;10(3):e0121861. doi: 10.1371/journal.pone.0121861. eCollection 2015. PLoS One. 2015. PMID: 25756736 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical